15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering Sanara Medtech Inc, 2 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $32.00 to $35.00, so the covering firms are broadly aligned. The average target of $34.00 sits 3% below the current $35.07. The rating mix has stayed broadly stable, with Buy-side ratings easing from 4 to 2 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.18 next quarter toward $0.54 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Moderate Buy
Strong Buy00%
Buy267%
Hold133%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to Sanara Medtech Inc.
As of Sep, 2 of 3 firms rate SMTI a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
SMTI EPS & revenue forecast
EPS · NEXT QUARTER
$0.18
Range $0.18 – $0.18 · 1 analysts
Next period, 1 analysts expect Sanara Medtech Inc to earn $0.18 a share (range $0.18 – $0.18), versus — a year earlier. Full-year consensus is $0.20, growing to $0.54 the year after.
REVENUE · NEXT QUARTER
$31.2M
Range $31.2M – $31.2M · 1 analysts · +13% YoY
Revenue is expected to reach $31.2M (range $31.2M – $31.2M), +13.3% year-over-year. Full-year consensus is $116.6M, rising to $133.2M next year.
Top analysts covering Sanara Medtech Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SMTI.
#1
Ross Osborn
Cantor Fitzgerald · Rank #166
Buy
$46.00+31.2% to target
Overall win rate
33%
+ Follow
#2
Yi Chen
HC Wainwright & Co. · Rank #277
Hold
$35.00-0.2% to target
Overall win rate
33%
+ Follow
#3
Frank Takkinen
Lake Street · Rank #394
Buy
$32.00-8.8% to target
Overall win rate
26%
+ Follow
#4
IZ
Ilya Zubkov
Freedom Broker
Buy
$35.00-0.2% to target
Coverage
—
+ Follow
SMTI stock forecast FAQ
What is SMTI's average 12-month price target?+
The 3 analysts with a live target average $34.00 for Sanara Medtech Inc over the next 12 months, ranging from a $35.00 high to a $32.00 low.
Is SMTI stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 3 analyst ratings, 2 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for SMTI?+
The Street-high target is $35.00 (HC Wainwright & Co.), and the Street-low is $32.00 (Lake Street). The average of all 3 active targets is $34.00.
How many Wall Street analysts cover SMTI?+
3 analysts have an active rating on Sanara Medtech Inc, and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering SMTI?+
Among analysts who currently cover SMTI, Ross Osborn of Cantor Fitzgerald has the strongest overall Quantellect track record (Rank #166). Their current call is Buy with a $46.00 target.
What is Sanara Medtech Inc's projected EPS for next quarter?+
The consensus estimate is $0.18 per share (range $0.18 – $0.18) across 1 analysts. Full-year EPS is projected at $0.20, rising to $0.54 the following year.
How much revenue is Sanara Medtech Inc expected to report next quarter?+
Consensus revenue is $31.2M (range $31.2M – $31.2M). Full-year revenue is projected at $116.6M, growing to $133.2M next year.
Have analysts been upgrading or downgrading SMTI lately?+
As of Sep, 2 of 3 firms rate SMTI a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SMTI calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
